SA-CCRC-Development of Therapeutics and Vaccines Against Coccidioidomycosis.

SA-CCRC-球孢子菌病治疗方法和疫苗的开发。

• 批准号: 10541225
• 负责人: CHIUNG-YU HUNG
• 金额: $ 135.7万
• 依托单位: UNIVERSITY OF TEXAS SAN ANTONIO
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-01-01 至 2026-12-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10541225
• 关键词: Address; Affect; Antibiotic Resistance; Antifungal Agents; Area; Arizona; Azole resistance; Basic Science; Bioinformatics; California; Cells; Clinical; Clinical Research; Coccidioides; Coccidioides immitis; Coccidioides posadasii; Coccidioidomycosis; Communities; Data; Development; Disease Outcome; Drug Screening; Ensure; Evaluation; Funding; Genomics; Geographic Locations; Goals; Health; Health Care Costs; Immunity; Immunocompromised Host; Immunotherapeutic agent; Immunotherapy; In Vitro; Individual; Infection; Infrastructure; Institution; Investigator-Initiated Research; Knowledge; Libraries; Lung; Medical; Mentors; Messenger RNA; Modeling; Morbidity - disease rate; Mycoses; Office of Administrative Management; Persons; Pharmaceutical Preparations; Predisposition; Prevention; Research; Research Personnel; Research Project Grants; Resources; Risk; Scientist; Site; Southwestern United States; Structure; Talents; Technical Expertise; Techniques; Technology; Testing; The science of Mycology; Therapeutic; Time; Training; Translational Research; Treatment outcome; United States; Vaccines; career development; clinically significant; desert fever; design; drug development; experience; high throughput screening; improved; in vivo; industry partner; instrumentation; member; new technology; next generation; novel; operation; programs; research and development; therapeutic development; translational pipeline; vector-based vaccine

Summary (Overall) San Antonio has a rich tradition of excellence in the field of Medical Mycology, including Coccidioidomycosis, also referred to as Valley Fever. These infections affect hundreds of thousands of healthy and immunocompromised individuals in the endemic areas of the arid Southwest U.S., with a majority of cases in California and Arizona. There are very few drugs to treat these infections and no vaccine is available. Growing levels of antibiotic resistance are a major concern, and the latest data on the expansion of the geographical area of infection is very worrisome. To address these major shortcomings, we propose the establishment of the San Antonio-based Coccidioidomycosis Collaborative Research Center (SA-CCRC). The new Center will be a highly collaborative place for synergistic multi- and interdisciplinary interactions by members of the Center, which include highly experienced investigators in the field of Coccidioides research, as well as others with substantial knowledge and/or technical expertise in other areas whose talents are being attracted to this field for the very first time. Overall, the SA-CCRC creates an optimal cohesive infrastructure to support integrated research, leverages resources at each of the participating sites and organizations, and also extends to the establishment of novel academic- industrial partnerships. Our Center has a strong translational emphasis, being distinctively focused on the development of antifungal drugs and vaccines against coccidioidomycosis. The center is anchored by an administrative core which will serve a central hub for providing the necessary organizational, administrative and financial oversight structure for the Center’s day-to-day operations. The overall objectives for the SA- CCRC are: i) to advance basic, translational and clinical research in the field of Coccidioidomycosis via investigator-driven research projects, ii) to adapt, develop and implement state of the art techniques to the Coccidioidomycosis field of research in support of the three different projects and the coccidioidomycosis community at large, and iii) to administer a Development and Research Program for pilot funding and mentoring of junior investigators and those new to the field of coccidioidomycosis. Altogether, the proposed SA-CCRC program will fill critical voids and will have a powerful and sustainable effect on the field of coccidioidomycosis research.

摘要（总体） 圣安东尼奥在医学真菌学领域拥有丰富的卓越传统，包括 球孢子菌病，也称为谷热，这些感染影响了数十万人。 美国西南部干旱流行区的健康和免疫功能低下的个体 大多数病例发生在加利福尼亚州和亚利桑那州，治疗这些感染的药物很少，也没有。 抗生素耐药性的不断增加是一个主要问题，而最新的数据则表明了这一点。 感染地理区域的扩大非常令人担忧。 我们提议建立位于圣安东尼奥的球孢子菌病合作研究中心 新中心将成为一个高度协作的多方协作场所。 该中心成员的跨学科互动，其中包括经验丰富的研究人员 球孢子菌研究领域，以及其他具有丰富知识和/或技术专长的人 总体而言，SA-CCRC 在其他领域的人才首次被吸引到该领域。 创建一个最佳的有凝聚力的基础设施来支持综合研究，利用每个方面的资源 参与站点和组织，还延伸到建立新颖的学术- 我们的中心非常重视转化，特别关注 该中心致力于开发抗球孢子菌病的抗真菌药物和疫苗。 行政核心，将作为一个中心枢纽，提供必要的组织、行政 中心日常运营的财务监督结构 SA 的总体目标。 CCRC 的目标是： i) 通过以下方式推进球孢子菌病领域的基础、转化和临床研究： 研究者驱动的研究项目，ii) 适应、开发和实施最先进的技术 球孢子菌病研究领域支持三个不同的项目和球孢子菌病 整个社区，以及 iii) 管理开发和研究计划以获取试点资金和 总而言之，建议对初级研究人员和球孢子菌病领域的新手进行指导。 SA-CCRC 计划将填补关键空白，并将对该领域产生强大且可持续的影响 球孢子菌病研究。